PDL BioPharma Reports Q3 EPS Above View, Revenue Below Street View

PDL BioPharma reports Q3 EPS 29c vs street view of 26c. PDL BioPharma (Nasdaq: PDLI) reports Q3 revenue $71.4M vs consensus of $76.48M.

PDL BioPharma lowers FY09 revenue guidance to $310M to $320M. PDL previously had seen FY09 revenue of $319M to $325M versus the street view of $331.96M.


There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

Post new comment

The content of this field is kept private and will not be shown publicly.